Philip Wells
Overview
Explore the profile of Philip Wells including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2522
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al.
Chest
. 2016 Feb;
149(2):315-352.
PMID: 26867832
Background: We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics. Methods: We generate strong (Grade 1) and weak (Grade...
22.
Rodger M, Le Gal G, Wells P, Baglin T, Aujesky D, Righini M, et al.
Thromb Res
. 2014 Aug;
134(4):763-8.
PMID: 25129416
Venous thromboembolism (VTE) is a potentially lethal clinical condition that is suspected in patients with common clinical complaints, in many and varied, clinical care settings. Once VTE is diagnosed, optimal...
23.
Wells P, Anderson D
Hematology Am Soc Hematol Educ Program
. 2013 Dec;
2013:457-63.
PMID: 24319219
Venous thromboembolism (VTE) is a common condition that can lead to complications such as postphlebitic syndrome, chronic pulmonary artery hypertension, and death. The approach to the diagnosis of has evolved...
24.
Anderson D, Dunbar M, Bohm E, Belzile E, Kahn S, Zukor D, et al.
Ann Intern Med
. 2013 Jun;
158(11):800-6.
PMID: 23732713
Background: The role of aspirin in thromboprophylaxis after total hip arthroplasty (THA) is controversial. Objective: To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE)...
25.
Hogg K, Kimpton M, Carrier M, Coyle D, Forgie M, Wells P
JAMA Intern Med
. 2013 May;
173(12):1067-72.
PMID: 23689427
Importance: Future funding for new treatments in venous thromboembolism will be guided by cost-utility analyses. There is little available information on the utility of acute venous thromboembolism, limiting the validity...
26.
McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, et al.
J Med Econ
. 2012 Apr;
15(5):817-28.
PMID: 22494267
Objectives: A cost-effectiveness model for rivaroxaban evaluated the cost-effectiveness of prophylaxis with rivaroxaban (a once-daily, orally administered Factor Xa inhibitor) vs enoxaparin in the prevention of venous thromboembolism (VTE) after...
27.
Antoni G, Oudot-Mellakh T, Dimitromanolakis A, Germain M, Cohen W, Wells P, et al.
BMC Med Genet
. 2011 Aug;
12:102.
PMID: 21810271
Background: Elevated levels of factor VIII (FVIII) and von Willebrand Factor (vWF) are well-established risk factors for cardiovascular diseases, in particular venous thrombosis. Although high, the heritability of these traits...
28.
Gretarsdottir S, Baas A, Thorleifsson G, Holm H, den Heijer M, de Vries J, et al.
Nat Genet
. 2010 Jul;
42(8):692-7.
PMID: 20622881
We performed a genome-wide association study on 1,292 individuals with abdominal aortic aneurysms (AAAs) and 30,503 controls from Iceland and The Netherlands, with a follow-up of top markers in up...
29.
Crowther M, Garcia D, Ageno W, Wang L, Witt D, Clark N, et al.
Thromb Haemost
. 2010 May;
104(1):118-21.
PMID: 20458438
Unanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarin-treated patients with INR values of more than 10 who received...
30.
Kearon C, Julian J, Kovacs M, Anderson D, Wells P, Mackinnon B, et al.
Blood
. 2008 Sep;
112(12):4432-6.
PMID: 18791166
We sought to determine whether thrombophilic defects increase recurrent venous thromboembolism (VTE) during warfarin therapy. Six hundred sixty-one patients with unprovoked VTE who were randomized to extended low-intensity (international normalized...